Carioli G, Bertuccio P, Boffetta P, Levi F, La Vecchia C, Negri E, et al. European cancer mortality predictions for the year 2020 with a focus on prostate cancer. Ann Oncol. 2020;31:650–8.

Article  CAS  PubMed  Google Scholar 

Hamid AA, Sayegh N, Tombal B, Hussain M, Sweeney CJ, Graff JN, et al. Metastatic hormone-sensitive prostate cancer: toward an era of adaptive and personalized treatment. Am Soc Clin Oncol Educ Book. 2023;43:e390166.

Article  PubMed  Google Scholar 

Ferretti S, Mercinelli C, Marandino L, Litterio G, Marchioni M, Schips L. Metastatic castration-resistant prostate cancer: insights on current therapy and promising experimental drugs. Res Rep Urol. 2023;15:243–59.

CAS  PubMed  PubMed Central  Google Scholar 

Berruti A, Bracarda S, Caffo O, Cortesi E, D’Angelillo R, Del Re M, et al. nmCRPC, a look in the continuous care of prostate cancer patients: state of art and future perspectives. Cancer Treat Rev. 2023;115:102525.

Article  CAS  PubMed  Google Scholar 

Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367:1187–97.

Article  CAS  PubMed  Google Scholar 

Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014;371:424–33.

Article  PubMed  PubMed Central  Google Scholar 

Sternberg CN, Fizazi K, Saad F, Shore ND, De Giorgi U, Penson DF, et al. Enzalutamide and survival in nonmetastatic, castration-resistant prostate cancer. N Engl J Med. 2020;382:2197–206.

Article  CAS  PubMed  Google Scholar 

Hussain M, Fizazi K, Saad F, Rathenborg P, Shore N, Ferreira U, et al. Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer. N Engl J Med. 2018;378:2465–74.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Armstrong AJ, Szmulewitz RZ, Petrylak DP, Holzbeierlein J, Villers A, Azad A, et al. ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer. J Clin Oncol. 2019;37:2974–86.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sweeney CJ, Martin AJ, Stockler MR, Begbie S, Cheung L, Chi KN, et al. Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial. Lancet Oncol. 2023;24:323–34.

Article  CAS  PubMed  Google Scholar 

Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Bmj. 2021;372:n71.

Article  PubMed  PubMed Central  Google Scholar 

Freedland SJ, de Almeida Luz M, De Giorgi U, Gleave M, Gotto GT, Pieczonka CM, et al. Improved outcomes with enzalutamide in biochemically recurrent prostate cancer. N Engl J Med. 2023;389:1453–65.

Article  CAS  PubMed  Google Scholar 

Attard G, Murphy L, Clarke NW, Cross W, Jones RJ, Parker CC, et al. Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol. Lancet. 2022;399:447–60.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kaplan I, Bubley GJ, Bhatt RS, Taplin ME, Dowling S, Mahoney K, et al. Enzalutamide with radiation therapy for intermediate-risk prostate cancer: a phase 2 study. Int J Radiat Oncol Biol Phys. 2021;110:1416–22.

Article  PubMed  Google Scholar 

Lara PC, Rodríguez-Melcón JI, Palacios-Eito A, Lozano A, Hervás-Morón A, Villafranca E, et al. Phase II study of ENZAlutamide combined with hypofractionated radiation therapy (ENZART) for localized intermediate risk prostate cancer. Front Oncol. 2022;12:891886.

Article  CAS  PubMed  PubMed Central  Google Scholar 

McKay RR, Ye H, Xie W, Lis R, Calagua C, Zhang Z, et al. Evaluation of intense androgen deprivation before prostatectomy: a randomized phase II trial of enzalutamide and leuprolide with or without abiraterone. J Clin Oncol. 2019;37:923–31.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Montgomery B, Tretiakova MS, Joshua AM, Gleave ME, Fleshner N, Bubley GJ, et al. Neoadjuvant enzalutamide prior to prostatectomy. Clin Cancer Res. 2017;23:2169–76.

Article  CAS  PubMed  Google Scholar 

Shee K, de la Calle CM, Chang AJ, Wong AC, Feng FY, Gottschalk AR, et al. Addition of enzalutamide to leuprolide and definitive radiation therapy is tolerable and effective in high-risk localized or regional nonmetastatic prostate cancer: results from a phase 2 trial. Adv Radiat Oncol. 2022;7:100941.

Article  PubMed  PubMed Central  Google Scholar 

Shore ND, Renzulli J, Fleshner NE, Hollowell CMP, Vourganti S, Silberstein J, et al. Enzalutamide monotherapy vs active surveillance in patients with low-risk or intermediate-risk localized prostate cancer: the ENACT randomized clinical trial. JAMA Oncol. 2022;8:1128–36.

Article  PubMed  PubMed Central  Google Scholar 

Bitting RL, Healy P, George DJ, Anand M, Kim S, Mayer T, et al. Phase II trial of enzalutamide and androgen deprivation therapy with salvage radiation in men with high-risk prostate-specific antigen recurrent prostate cancer: the STREAM trial. Eur Urol Oncol. 2021;4:948–54.

Article  PubMed  Google Scholar 

Madan RA, Karzai F, Donahue RN, Al-Harthy M, Bilusic M, Rosner II, et al. Clinical and immunologic impact of short-course enzalutamide alone and with immunotherapy in non-metastatic castration sensitive prostate cancer. J Immunother Cancer. 2021;9:e001556.

Tombal B, Borre M, Rathenborg P, Werbrouck P, Van Poppel H, Heidenreich A, et al. Long-term antitumor activity and safety of enzalutamide monotherapy in hormone Naïve prostate cancer: 3-year open label followup results. J Urol. 2018;199:459–64.

Article  CAS  PubMed  Google Scholar 

Tran PT, Lowe K, Tsai HL, Song DY, Hung AY, Hearn JWD, et al. Phase II randomized study of salvage radiation therapy plus enzalutamide or placebo for high-risk prostate-specific antigen recurrent prostate cancer after radical prostatectomy: the SALV-ENZA trial. J Clin Oncol. 2023;41:1307–17.

Article  CAS  PubMed  Google Scholar 

Mottet NCP, van den Bergh RCN, et al. EAU guidelines 2023 [Available from: https://uroweb.org/guidelines/prostate-cancer/chapter/treatment.

Gómez Rivas J, Gandaglia G, Montorsi F. Re: Neal D. Shore, Joseph Renzulli, N E. Fleshner, et al. Active Surveillance plus Enzalutamide Monotherapy vs Active Surveillance Alone in Patients with Low-risk or Intermediate-risk Localized Prostate Cancer: The ENACT Randomized Clinical Trial. JAMA Oncol 2022;8:1128-36: Let’s Not Go Back in Time! What Have We Learned in the Treatment of Localized Prostate Cancer? Applicability of the ENACT Randomized Clinical Trial in Clinical Practice. Eur Urol Open Sci. 2022;46:135–6.

Article  PubMed  PubMed Central  Google Scholar 

Stephenson AJ, Kattan MW, Eastham JA, Bianco FJ Jr, Yossepowitch O, Vickers AJ, et al. Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era. J Clin Oncol. 2009;27:4300–5.

Article  PubMed  PubMed Central  Google Scholar 

Liu W, Yao Y, Liu X, Liu Y, Zhang GM. Neoadjuvant hormone therapy for patients with high-risk prostate cancer: a systematic review and meta-analysis. Asian J Androl. 2021;23:429–36.

Article  PubMed  PubMed Central  Google Scholar 

Kumar S, Shelley M, Harrison C, Coles B, Wilt TJ, Mason MD. Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer. Cochrane Database Syst Rev. 2006;2006:Cd006019.

PubMed  PubMed Central  Google Scholar 

Krauss DJ, Karrison T, Martinez AA, Morton G, Yan D, Bruner DW, et al. Dose-escalated radiotherapy alone or in combination with short-term androgen deprivation for intermediate-risk prostate cancer: results of a phase III multi-institutional trial. J Clin Oncol. 2023;41:3203–16.

Article  CAS  PubMed  Google Scholar 

Bolla M, Maingon P, Carrie C, Villa S, Kitsios P, Poortmans PM, et al. Short androgen suppression and radiation dose escalation for intermediate- and high-risk localized prostate cancer: results of EORTC trial 22991. J Clin Oncol. 2016;34:1748–56.

Article  CAS  PubMed  Google Scholar 

Jones CU, Hunt D, McGowan DG, Amin MB, Chetner MP, Bruner DW, et al. Radiotherapy and short-term androgen deprivation for localized prostate cancer. N Engl J Med. 2011;365:107–18.

Article  CAS  PubMed  Google Scholar 

Taylor LG, Canfield SE, Du XL. Review of major adverse effects of androgen-deprivation therapy in men with prostate cancer. Cancer. 2009;115:2388–99.

Article  PubMed  Google Scholar 

Roy S, Romero T, Michalski JM, Feng FY, Efstathiou JA, Lawton CAF, et al. Biochemical recurrence surrogacy for clinical outcomes after radiotherapy for adenocarcinoma of the prostate. J Clin Oncol. 2023;41:5005–14.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tree A, Griffin C, Syndikus I, Birtle A, Choudhury A, Graham J, et al. Nonrandomized Comparison of Efficacy and Side Effects of Bicalutamide Compared With Luteinizing Hormone-Releasing Hormone (LHRH) analogs in combination with radiation therapy in the CHHiP trial. Int J Radiat Oncol Biol Phys. 2022;113:305–15.

Article  PubMed  PubMed Central  Google Scholar 

Schmidt-Hegemann N-S, Zamboglou C, Mason M, Mottet N, Hinnen K, De Meerleer G, et al. ESTRO-ACROP recommendations for evidence-based use of androgen deprivation therapy in combination with external-beam radiotherapy in prostate cancer. Radiother Oncol. 2023;183:109544.

Article  CAS  PubMed